Androgenic Inactivation of FKHR in Prostate Cancer

前列腺癌中 FKHR 的雄激素失活

• 批准号: 7082854
• 负责人: DONALD J. TINDALL
• 金额: $ 24.95万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2007-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7082854
• 关键词: androgens; apoptosis; benign prostate hyperplasia; cell growth regulation; cytotoxicity; endopeptidases; hormone regulation /control mechanism; mass spectrometry; prostate neoplasms; protein purification; protein sequence; protein structure function; proteolysis; site directed mutagenesis; tissue /cell culture; transcription factor

DESCRIPTION (provided by applicant): Benign prostate hyperplasia (BPH) and prostate cancer are two major health problems of men in this country. The androgen receptor is critical for both growth and survival of benign and cancerous prostate cells. Mitogenic effects of androgens are mediated in part by androgen-induced increases in proliferation-promoting proteins, such as proliferating cell nuclear antigen (PCNA), cyclin-dependent kinases 2 and 4, as well as decreases in cell cycle inhibitors, such as cyclin-dependent kinase inhibitor p16 ink4a. Although the mechanistic details of the anti-apoptotic effects of androgens are far from elucidated, progress has been made recently in our laboratory and others. We and others have demonstrated that androgens act as survival factors by antagonizing the function of the tumor suppressor gene PTEN. An effector downstream of PTEN, the forkhead transcription factor FKHR, plays a critical role in apoptosis by inducing the transcription of proapoptotic genes. We and others have shown that forced expression of FKHR induces apoptosis in prostate cancer cells, suggesting that FKHR is a critical pro-apoptotic player in prostate cancer cells. Our data have demonstrated that androgens abrogate FKHR-induced death of prostate cancer cells. Moreover, we have demonstrated that androgens inhibit the activity of FKHR by regulating lysosome-mediated proteolysis of this protein. Thus, we hypothesize that androgens antagonize death of prostate cells at least in part via their inhibitory effects on the pro-apoptotic function of FKHR. To test this hypothesis, we propose to (1) determine the proteolytic cleavage site in the FKHR protein; (2) identify the androgen-regulated protease(s) that cleaves FKHR; (3) determine whether blockage of the effect of androgens on FKHR favors the death of prostate cancer cells. These findings should enhance our understanding of the action of androgens on growth and survival of both normal and malignant prostate cells. Also, identification of such novel proteins will enable us to better manipulate androgen-regulated events in BPH and prostate cancer.

描述（由申请人提供）： 良性前列腺增生（BPH）和前列腺癌是该国男性的两个主要健康问题。雄激素受体对于良性和癌细胞细胞的生长和存活至关重要。雄激素诱导的促进蛋白的增加介导了雄激素的有丝分裂作用，例如增殖细胞核抗原（PCNA），细胞周期蛋白依赖性激酶2和4，以及细胞周期抑制剂的降低，例如细胞周期抑制剂，例如依赖细胞周期依赖性激素激酶依赖性激酶抑制剂P16 Ink4a。尽管雄激素抗凋亡作用的机理细节远非阐明，但最近在我们的实验室和其他方面取得了进展。我们和其他人已经证明，雄激素通过拮抗肿瘤抑制基因PTEN的功能来充当生存因子。 PTEN的下游效应子，即叉头转录因子FKHR，通过诱导促凋亡基因的转录来在凋亡中起关键作用。我们和其他人表明，FKHR强迫表达在前列腺癌细胞中诱导凋亡，这表明FKHR是前列腺癌细胞中关键的促凋亡者。我们的数据表明，雄激素消除了FKHR诱导的前列腺癌细胞死亡。此外，我们已经证明，雄激素通过调节该蛋白质的溶酶体介导的蛋白水解来抑制FKHR的活性。因此，我们假设雄激素至少部分通过其对FKHR促凋亡功能的抑制作用至少部分地拮抗前列腺细胞的死亡。为了检验该假设，我们建议（1）确定FKHR蛋白中的蛋白水解切割位点； （2）确定裂解FKHR的雄激素调节的蛋白酶； （3）确定雄激素对FKHR的影响是否有利于前列腺癌细胞的死亡。这些发现应增强我们对雄激素对正常和恶性前列腺细胞生长和存活的作用的理解。同样，这种新型蛋白质的鉴定将使我们能够更好地操纵BPH和前列腺癌中的雄激素调节的事件。